CASE STUDY

Diffuse Involvement of Primary Colorectal Lymphoma Simulating Ulcerative Colitis

Ji-Ye Kim, Sun Hee Chang, Hangseong Kim, Mee Joo
Department of Pathology, Inje University Ilsan Paik Hospital, Goyang, Korea

Running title: Diffuse type primary colorectal lymphoma

Corresponding Author

Mee Joo, M.D., Ph.D.
Department of Pathology, Inje University Ilsan Paik Hospital, Juhwa-ro 170, Goyang-si, 10380, Korea
Tel: +82-31-910-7141
Fax: +82-31-910-7139
E-mail: mjoo@paik.ac.kr
ABSTRACT
Diffuse involvement of colorectal lymphoma masquerading as colitis is a very rare presentation of primary colorectal lymphoma. Detecting occult lymphoma is difficult in the setting of diffuse colonic involvement with no definite mass and inflammatory mucosal changes. We encountered a case of diffuse type primary colorectal lymphoma simulating ulcerative colitis in a previously healthy 31-year-old woman. Despite multiple mucosal biopsies, the biopsy diagnosis was not made due to unawareness of atypical lymphocytes admixed with dense lymphoplasmacytic infiltration. The present case emphasizes the importance of being aware of this rare presentation of primary colorectal lymphoma in order to avoid misdiagnosis.

Key Words: Colorectal lymphoma; Primary; Diffuse type; Colitis
The incidence of primary colorectal lymphoma is very rare, accounting for 0.2%-0.6% of colorectal malignancies. Primary colorectal lymphomas manifest in a variety of ways, ranging from solitary fungating masses to multiple polyps. In 1968, Friedman et al reported 4 cases of “lymphomatous colitis,” a rare form of primary colorectal lymphoma mimicking ulcerative colitis (UC). Since then, a small number of patients with diffuse type colorectal lymphoma have been reported, in whom a clinical and/or histological diagnosis of colitis, including inflammatory bowel disease (IBD), was made initially but were subsequently discovered to have diffuse lymphoma involvement of the colon within a short period of time. IBD and immunosuppression have been reported as risk factors for primary colorectal lymphoma. Most IBD-related lymphomas develop late in the course of an extensive longstanding disease. In that respect, these cases differ from most reports of primary colorectal lymphoma as a complication of longstanding IBD. We experienced a case of UC-like primary colorectal lymphoma in a 31-year-old woman who presented with profuse hematochezia, was misdiagnosed with UC, and died of a diffuse lymphoma involving the entire colon 12 months after hematochezia first developed.

**CASE REPORT**

A 31-year-old woman with no prior histology of IBD presented with intermittent abdominal pain and mucoid diarrhea. Five months later, she developed hematochezia and was diagnosed with UC on the basis of endoscopic biopsy. She was treated with oral Pentasa and Pentasa enema. However, she continued to be symptomatic with marked weight loss (20 kg in 4 months). Follow-up colonoscopy revealed continuous mucosal changes from the rectum to the cecum, such as diffuse hyperemia, edematous changes, friability, loss of normal vascularity, and multiple variable-sized ulcers, consistent with ulcerative colitis (Fig. 1A). No mass-forming lesion was present throughout. Abdominal and pelvic computed tomography revealed diffuse edematous wall thickening in the whole colon and multiple enlargements of mesenteric lymph nodes. No hepatosplenomegaly was observed. Multiple biopsies were taken from the terminal ileum, cecum, transverse colon, sigmoid colon, and rectum. All biopsy specimens revealed diffuse infiltration of large, atypical lymphoid cells with a high nucleus to
cytoplasmic ratio, occasional prominent nucleoli, and mitotic figures (Fig. 1B & 1C). They expanded the lamina propria, pushed the crypts apart, and invaded the submucosa. By immunohistochemistry, the tumor cells were diffusely positive for CD20, bcl2, and p53, and negative for CD3, CD5, CD10, and cyclin D1. The Ki-67 labeling index was about 60%. The overall histology and immunophenotype supported a diagnosis of diffuse large B cell lymphoma. There was no detectable evidence of extraabdominal lymphadenopathy or lymphomatous involvement elsewhere. Bone marrow evaluation was also negative for lymphoma. As no extraintestinal disease was found, we considered it as a primary colorectal lymphoma. The patient died while receiving the second cycle of R-CHOP chemotherapy.

We retrospectively reviewed the colonoscopic biopsy specimens that were initially diagnosed with UC. At low magnification view, the background mucosa displayed crypt architectural distortion and dense inflammatory cell infiltration, resembling chronic colitis. However, we found some lymphoma cells, which were admixed with other inflammatory cells or showed focal aggregation in the basal portion of the mucosa (Fig. 1D). Those lymphoma cells were more distinguishable on immunostaining for CD20 and Ki-67 (Fig. 1E & 1F).

This study was approved by the Institutional Review Board of Inje University Ilsan Paik Hospital with a waiver of informed consent (IRB No. ISPAIK 2019-05-005) and performed in accordance with the principles of the Declaration of Helsinki.

**DISCUSSION**

Twenty cases (including the present one) of “colitis-like” diffuse type colorectal lymphoma were reported in the English literature.2-17 We excluded cases of colorectal lymphoma developed in patients with a longstanding IBD or prior established diagnosis of extracolonic lymphoma. The clinical and pathological findings of these patients are summarized in Table 1. There were 10 men, 8 women, and two children. Their mean age at presentation was 53.2 years (range: 6–82). The main symptoms were diarrhea/hematochezia (90%), loss of weight (50%), abdominal pain (25%), and fever (10%). Endoscopic findings were consistent with ulcerative colitis (55%), Crohn’s disease (20%), diffuse
colitis (20%), and multiple ulcers (5%): No localized mass-like lesion was present. All cases were non-Hodgkin’s lymphoma: 8 were B cell type (4 mantle cell lymphomas, 2 MALT lymphomas, 1 diffuse large B cell lymphoma, and 1 follicular lymphoma), 7 were T cell type, 1 was natural killer (NK) cell lymphoma, and 4 other unclassified lymphoreticular malignancies (1 malignant lymphoma, 1 reticulum cell sarcoma, 1 lymphosarcoma, and 1 lymphocytic lymphoma). Of note, there were 9 patients in whom colitis was histologically confirmed with multiple biopsy or colectomy but were subsequently found to have lymphoma involvement in a retrospective review of previous slides. Taken together, diffuse type primary colorectal lymphoma is a very rare disease and is easily misdiagnosed, particularly in reliance on endoscopic biopsy examination alone. The possibility of a hidden lymphomatous involvement would have to be considered in patients with medically refractory and rapidly progressive colitis.

Lymphoma involvement of the gastrointestinal (GI) tract may occur either as an isolated primary neoplasm or as a manifestation of systemic generalized lymphoma. To distinguish between primary and secondary GI lymphoma, Dawson’s criteria is generally applied: 1) no palpable superficial lymphadenopathy at initial presentation; 2) a normal chest X-ray with no mediastinal lymphadenopathy; 3) no evidence of leukemia; 4) a predominant mass in the bowel with only local lymphadenopathy; and 5) no hepatosplenomegaly. When the diagnostic criteria of primary colonic lymphoma are strictly applied, only 7 of 20 cases of "colitis-like" colorectal lymphoma are eligible for diffuse type primary colorectal lymphoma: 13 cases were excluded due to synchronous other organ involvement at initial presentation, such as superficial or generalized lymphadenopathy (6 cases), upper GI involvement (5 cases), bone marrow involvement (4 cases), or hepatosplenomegaly (3 cases), etc. Consequently, it is a reflection that “colitis-like” diffuse involvement of colorectal lymphoma seems to be more often secondary. Accurate discrimination between primary and secondary colorectal lymphoma is important for proper staging and management. In conclusion, since primary colorectal lymphoma can rarely manifest as “colitis-like” diffuse colonic involvement, awareness of this rare presentation is important to ensure proper diagnosis and treatment.
Author Contributions
Conceptualization: MJ
Investigation: MJ
Visualization: MJ
Writing - original draft: JYK, MJ
Writing - review & editing: JYK, MJ, SHC, HSK

Conflicts of Interest
The authors declare that they have no potential conflicts of interest.

REFERENCES
Table 1. Clinical and pathological findings of previously published cases of “colitis-like” diffuse type colorectal lymphomas in the English literature.

<table>
<thead>
<tr>
<th>Year</th>
<th>Authors</th>
<th>Gender/Age</th>
<th>Pathologic diagnosis</th>
<th>Endoscopic findings</th>
<th>Revision of initial diagnosis</th>
<th>Superficial LAP at presentation</th>
<th>Extracolonic involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1968</td>
<td>Friedman et al.²</td>
<td>M/37</td>
<td>Reticulum cell sarcoma</td>
<td>UC</td>
<td>No</td>
<td>No</td>
<td>Liver</td>
</tr>
<tr>
<td>1968</td>
<td>Friedman et al.²</td>
<td>F/54</td>
<td>Malignant lymphoma</td>
<td>UC</td>
<td>Yes (colectomy)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>1968</td>
<td>Friedman et al.²</td>
<td>M/73</td>
<td>Lymphosarcoma</td>
<td>UC</td>
<td>Yes (Bx)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>Weir et al.³</td>
<td>F/67</td>
<td>Lymphocytic lymphoma</td>
<td>CD</td>
<td>Yes (Bx)</td>
<td>Yes, generalized</td>
<td>BM</td>
</tr>
<tr>
<td>1992</td>
<td>McCullough et al.⁴</td>
<td>M/44</td>
<td>Mantle cell lymphoma</td>
<td>UC</td>
<td>Yes (Bx)</td>
<td>Yes, cervical axillary</td>
<td>Pancreas</td>
</tr>
<tr>
<td>1995</td>
<td>Lenzen R et al.⁵</td>
<td>F/53</td>
<td>MALT lymphoma</td>
<td>UC</td>
<td>No</td>
<td>No</td>
<td>Upper GI tract, BM</td>
</tr>
<tr>
<td>1996</td>
<td>Robert et al.⁶</td>
<td>F/71</td>
<td>Mantle cell lymphoma</td>
<td>UC</td>
<td>Yes (colectomy)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>Hirakawa et al.⁷</td>
<td>M/47</td>
<td>T cell lymphoma</td>
<td>UC</td>
<td>No</td>
<td>No</td>
<td>Upper GI tract</td>
</tr>
<tr>
<td>1997</td>
<td>Son et al.⁸</td>
<td>F/40</td>
<td>Peripheral T cell lymphoma</td>
<td>CD</td>
<td>Yes (Bx)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Isomoto et al.⁹</td>
<td>M/47</td>
<td>Adult T-cell leukemia/lymphoma</td>
<td>UC</td>
<td>No</td>
<td>Yes, generalized</td>
<td>stomach, skin</td>
</tr>
<tr>
<td>2004</td>
<td>Payne et al.¹⁰</td>
<td>F/76</td>
<td>High grade T cell lymphoma</td>
<td>Colitis</td>
<td>No</td>
<td>Yes, generalized</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Tamura et al.¹¹</td>
<td>M/61</td>
<td>Mantle cell lymphoma</td>
<td>Colitis</td>
<td>No</td>
<td>No</td>
<td>tonsil, upper GI tract</td>
</tr>
<tr>
<td>2008</td>
<td>Berkelhammer et al.¹²</td>
<td>F/82</td>
<td>MALT lymphoma</td>
<td>CD</td>
<td>Yes (Bx)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Author(s)</td>
<td>Age</td>
<td>Sex</td>
<td>Diagnosis</td>
<td>UC</td>
<td>CD</td>
<td>LAP</td>
</tr>
<tr>
<td>------</td>
<td>----------------</td>
<td>-----</td>
<td>-----</td>
<td>-----------------------------------------------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>2014</td>
<td>Koksal et al.</td>
<td>M/73</td>
<td>M</td>
<td>Mantle cell lymphoma</td>
<td>UC</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2015</td>
<td>Zaheen et al.</td>
<td>M/74</td>
<td>M</td>
<td>EBV-negative NK cell lymphoma</td>
<td>Colitis</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2015</td>
<td>Wu et al.</td>
<td>M/56</td>
<td>M</td>
<td>T cell lymphoma</td>
<td>Ulcers</td>
<td>Yes (Bx)</td>
<td>Yes, generalized</td>
</tr>
<tr>
<td>2016</td>
<td>Cheung et al.</td>
<td>12</td>
<td>M</td>
<td>EBV-positive T cell lymphoma</td>
<td>Colitis</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2016</td>
<td>Cheung et al.</td>
<td>6</td>
<td>M</td>
<td>EBV-positive T cell lymphoma</td>
<td>CD</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2017</td>
<td>Zenda et al.</td>
<td>M/59</td>
<td>M</td>
<td>Follicular lymphoma</td>
<td>UC</td>
<td>No</td>
<td>Yes, cervical inguinal, Spleen, BM</td>
</tr>
<tr>
<td></td>
<td>Present case</td>
<td>F/32</td>
<td>F</td>
<td>Diffuse large B cell lymphoma</td>
<td>UC</td>
<td>Yes (Bx)</td>
<td>No</td>
</tr>
</tbody>
</table>

UC, ulcerative colitis; CD, Crohn’s disease; Bx, biopsy; LAP, lymphadenopathy; BM, bone marrow, GI, gastrointestinal.

FIGURE LEGENDS
Figure 1. (A) Colonoscopy reveals diffuse hyperemic inflamed mucosa with total loss of normal vascularity & surface ulceration from the rectum to the cecum. (B & C) Representative microphotographs of diffuse lymphoma involvement on the biopsy specimens. (B) The mucosa and submucosa are diffusely involved by densely packed lymphocytes with the background remnants of colonic crypts. Monotonous large-sized lymphocytes have vesicular chromatin and often membrane-
bound nucleoli, resembling centroblasts (C). (D-F) Retrospective examination of initial colonoscopic biopsy. (D) The biopsied colonic mucosa displays crypt architectural distortion and dense inflammatory cell infiltration, resembling chronic colitis. Atypical lymphoid cells are aggregated in the bottom right corner (below the yellow dotted line), which show not only strong expression on CD20 immunostaining (E) but also high Ki-67 labeling index (F).